Literature DB >> 3710581

Susceptibility of Campylobacter jejuni to strain-specific bactericidal activity in sera of infected patients.

R A Pennie, R D Pearson, L J Barrett, H Lior, R L Guerrant.   

Abstract

Campylobacter jejuni is a common cause of inflammatory enteritis, which in normal hosts is usually self-limited and resolves without antibiotic therapy. C. jejuni bacteremia is very rare. We examined sera for bactericidal activity that might be important in limiting the extent of C. jejuni infection in man. We studied the ability of nonimmune sera and homologous and heterologous immune sera from infected patients to kill different fresh case isolates of C. jejuni in vitro. The reduction of the log10 concentration of viable C. jejuni (log10 killing) by fresh sera from nonimmune donors was only 0.2. Log10 killing by homologous acute sera varied from 0 to 3.8 (mean, 1.8). Convalescent sera showed remarkable log10 killing of only homologous C. jejuni, with values of 2.7 to 4.4 (mean, 3.7). The bactericidal effects of acute and convalescent sera were abrogated by heat and EDTA chelation, indicating mediation by complement. The role of classical complement pathway activation was supported by chelating sera with magnesium EGTA [ethylene glycol-bis(beta-aminoethyl ether)-N, N, N', N'-tetraacetic acid] and by reconstitution experiments with heat-inactivated sera, C2-deficient serum, and purified C2. The requirement of specific antibody for the serum bactericidal effect was indicated by the loss of bactericidal activity when immune sera were absorbed with homologous but not heterologous whole C. jejuni isolates. The presence of specific antibodies was further documented by agglutination of only homologous C. jejuni suspensions by heat-inactivated immune sera. Studies with polymorphonuclear leukocytes suggested that ingestion and killing of two C. jejuni strains were modest and variable in the presence of heat-inactivated homologous serum. In summary, the data document a potent serum bactericidal effect that develops rapidly and specifically during C. jejuni enteritis and may be an important factor in host defense against C. jejuni.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3710581      PMCID: PMC260914          DOI: 10.1128/iai.52.3.702-706.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

Review 1.  Campylobacter enteritis.

Authors:  J P Butzler; M B Skirrow
Journal:  Clin Gastroenterol       Date:  1979-09

Review 2.  Campylobacter enteritis.

Authors:  M J Blaser; L B Reller
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

3.  Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis.

Authors:  B J Anders; B A Lauer; J W Paisley; L B Reller
Journal:  Lancet       Date:  1982-01-16       Impact factor: 79.321

4.  Bactericidal and opsonic activity against Neisseria gonorrhoeae in sera from patients with disseminated gonococcal infection.

Authors:  G F Brooks; K S Israel; B H Petersen
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

5.  Serotyping of Campylobacter jejuni by slide agglutination based on heat-labile antigenic factors.

Authors:  H Lior; D L Woodward; J A Edgar; L J Laroche; P Gill
Journal:  J Clin Microbiol       Date:  1982-05       Impact factor: 5.948

6.  Serum antibodies in Campylobacter enteritis.

Authors:  J Kaldor; H Pritchard; A Serpell; W Metcalf
Journal:  J Clin Microbiol       Date:  1983-07       Impact factor: 5.948

7.  Serologic study of two clusters of infection due to Campylobacter jejuni.

Authors:  M J Blaser; D J Duncan; M T Osterholm; G R Istre; W L Wang
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

8.  Campylobacter enteritis in the United States. A multicenter study.

Authors:  M J Blaser; J G Wells; R A Feldman; R A Pollard; J R Allen
Journal:  Ann Intern Med       Date:  1983-03       Impact factor: 25.391

9.  New, extended biotyping scheme for Campylobacter jejuni, Campylobacter coli, and "Campylobacter laridis".

Authors:  H Lior
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

10.  The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus.

Authors:  M S Edwards; A Nicholson-Weller; C J Baker; D L Kasper
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

View more
  14 in total

1.  Characterization of high-level quinolone resistance in Campylobacter jejuni.

Authors:  T D Gootz; B A Martin
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  Campylobacter jejuni isolations from Mexican and Swedish patients, with repeated symptomatic and/or asymptomatic diarrhoea episodes.

Authors:  E Sjögren; G Ruiz-Palacios; B Kaijser
Journal:  Epidemiol Infect       Date:  1989-02       Impact factor: 2.451

3.  Characterization of the dTDP-Fuc3N and dTDP-Qui3N biosynthetic pathways in Campylobacter jejuni 81116.

Authors:  Zack Z Li; Alexander S Riegert; Marie-France Goneau; Anna M Cunningham; Evgeny Vinogradov; Jianjun Li; Ian C Schoenhofen; James B Thoden; Hazel M Holden; Michel Gilbert
Journal:  Glycobiology       Date:  2017-04-01       Impact factor: 4.313

4.  Phase-Variable Changes in the Position of O-Methyl Phosphoramidate Modifications on the Polysaccharide Capsule of Campylobacter jejuni Modulate Serum Resistance.

Authors:  Brittany Pequegnat; Renee M Laird; Cheryl P Ewing; Christina L Hill; Eman Omari; Frederic Poly; Mario A Monteiro; Patricia Guerry
Journal:  J Bacteriol       Date:  2017-06-27       Impact factor: 3.490

5.  Metabolomics of Glioma.

Authors:  Sizhe Feng; Yutong Liu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Comparison of different vaccines and induced immune response against Campylobacter jejuni colonization in the infant mouse.

Authors:  A G Abimiku; J M Dolby; S P Borriello
Journal:  Epidemiol Infect       Date:  1989-04       Impact factor: 2.451

7.  Production of a unique cytotoxin by Campylobacter jejuni.

Authors:  R L Guerrant; C A Wanke; R A Pennie; L J Barrett; A A Lima; A D O'Brien
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

Review 8.  Host-pathogen interactions in Campylobacter infections: the host perspective.

Authors:  Riny Janssen; Karen A Krogfelt; Shaun A Cawthraw; Wilfrid van Pelt; Jaap A Wagenaar; Robert J Owen
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

9.  Human immune response to Campylobacter jejuni proteins expressed in vivo.

Authors:  P Panigrahi; G Losonsky; L J DeTolla; J G Morris
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

Review 10.  HIF-1α Metabolic Pathways in Human Cancer.

Authors:  Naseim Elzakra; Yong Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.